An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Chen, Christine I. [1 ]
Paul, Harminder [1 ]
Snitzler, Susi [1 ]
Le, Lisa W. [2 ]
Wei, Ellen Nong [1 ]
Lau, Anthea [2 ]
Johnston, James B. [3 ]
Gibson, Spencer B. [4 ]
Queau, Michelle L. [4 ]
Trudel, Suzanne [1 ]
机构：
[1] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
[3] Canc Care Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada
[4] Canc Care Manitoba, Res Inst Oncol & Hematol, Winnipeg, MB, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Preliminary Results From a Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide In Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
    Flinn, Ian W.
    Berdeja, Jesus G.
    Waselenko, Jamie K.
    Cooper, R. Seth
    Bi, Jia
    Shih, Kent
    Doss, Habib H.
    Dickson, Natalie
    Thompson, Dana S.
    Burris, Howard A., III
    Hainsworth, John D.
    BLOOD, 2010, 116 (21) : 1022 - 1022
  • [22] Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study.
    Abramson, Jeremy S.
    Davids, Matthew Steven
    Werner, Lillian
    Fisher, David Christopher
    Armand, Philippe
    Amrein, Philip C.
    Neuberg, Donna S.
    Hochberg, Ephraim P.
    Brown, Jennifer R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia (CLL): Preliminary data.
    Cazin, B
    Binet, JL
    Divine, M
    Lepretre, S
    Lederlin, P
    Travade, P
    Lemaire, G
    Guibon, O
    BLOOD, 2000, 96 (11) : 515A - 515A
  • [24] Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    Falchi, Lorenzo
    O'Brien, Susan
    Wierda, William
    Faderl, Stefan
    Smith, Susan C.
    Ayala, Ana B.
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2012, 120 (21)
  • [25] Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    Fischer, Kirsten
    Cramer, Paula
    Busch, Raymonde
    Boettcher, Sebastian
    Bahlo, Jasmin
    Schubert, Joeerg
    Pflueger, Karl H.
    Schott, Silke
    Goede, Valentin
    Isfort, Susanne
    von Tresckow, Julia
    Fink, Anna-Maria
    Buehler, Andreas
    Winkler, Dirk
    Kreuzer, Karl-Anton
    Staib, Peter
    Ritgen, Matthias
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Hallek, Michael
    Stilgenbauer, Stephan
    Wendtner, Clemens-Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) : 3209 - 3216
  • [26] 2-CHLORODEOXYADENOSINE (CDA) FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
    DELANNOY, A
    MARTIAT, P
    BOSLY, A
    FERRANT, A
    DENEYS, V
    MICHAUX, JL
    BLOOD, 1994, 84 (10) : A461 - A461
  • [27] A phase II study of sequential combination chemotherapy with cyclophosphamide (CTX), prednisone, and 2-chlorodeoxyadenosine (2-CDA) in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Tefferi, A
    Reeder, CB
    Geyer, SM
    Allmer, C
    Li, CY
    Levitt, R
    Michalak, JC
    Addo, F
    Krook, JE
    Witzig, TE
    Schaefer, PL
    Maillard, JA
    BLOOD, 2000, 96 (11) : 296B - 296B
  • [28] Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia (CLL).
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 360B - 361B
  • [29] Effectiveness of 2-chlorodeoxyadenosine (2-CDA) in previously untreated patients with chronic lymphocytic leukemia (CLL)
    Komarnicki, M
    Trepinska, E
    Kazmierczak, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 445 - 445
  • [30] Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)
    Pflug, N.
    Maurer, C.
    Bahlo, J.
    Kluth, S.
    Rhein, C.
    Cramer, P.
    Gross-Ophoff, C.
    Langerbeins, P.
    Fink, A. -M.
    Eichhorst, B.
    Kreuzer, K. -A.
    Tausch, E.
    Stilgenbauer, S.
    Boettcher, S.
    Doehner, H.
    Kneba, M.
    Hallek, M.
    Wendtner, C. -M.
    Bergmann, M.
    Fischer, K.
    Oncology Research and Treatment, 2015, 38 : 92 - 92
12345